VANCOUVER, BC / ACCESSWIRE / December 8, 2023 / Core One Labs Inc. (CSE: COOL ) (OTCQB: CLABF ) (Frankfurt: LD6 ) (WKN:A3CSSU) (the " Company " or " Core One ") is pleased to announce the signing of an Initial Agreement (the " Agreement ") with Cube Psytech Corp. (" Cube Psytech ") marking a significant step towards exploring the potential sale of biosynthetically produced psilocybin, or the licensing of its proprietary... Read More

VANCOUVER, BC / ACCESSWIRE / December 1, 2023 / Core One Labs Inc. ("Core One" or the "Company") (CNSX:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN: A3CSSU), an emerging leader in the field of neuroscience and psychedelics, is delighted to share the exciting results of its first round of Stage 2 animal model studies, carried out in collaboration with the Universitat de Barcelona on behalf of the Company's wholly owned subsidiary,... Read More

VANCOUVER, BC / ACCESSWIRE / August 4, 2023 / Core One Labs Inc. (CSE: COOL ) (OTCQB: CLABF ) (Frankfurt: LD6 , WKN:A3CSSU), (the " Company " or " Core One ") is delighted to announce the receipt of additional positive results from its second round (" Round 2 ") of Stage 1 animal model studies. The groundbreaking studies were conducted in collaboration with esteemed research partners at the Universitat de Barcelona, Spain,... Read More

Core One's Wholly-Owned Subsidiary has filed a patent application with the United States Patent and Trademark Office VANCOUVER, BC / ACCESSWIRE / August 1, 2023 / Core One Labs Inc. (CSE: COOL )(OTCQB: CLABF )(Frankfurt: LD6 , WKN:A3CSSU) (the " Company " or " Core One ") proudly announces a significant milestone in its pursuit of cutting-edge psychedelic research and development. Awakened Biosciences Inc. (" Awakened "),... Read More

VANCOUVER, BC / ACCESSWIRE / July 28, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN:A3CSSU) (the "Company" or "Core One"), is excited to share positive results from its first round of Stage 1 animal model studies ("Round 1"), conducted by its research partners at the Universitat de Barcelona ("University of Barcelona" or the "University" or the "Investigators"), Barcelona, Spain, on behalf of the... Read More

VANCOUVER, BC / ACCESSWIRE / July 11, 2023 / Core One Labs Inc. (CSE: COOL ), (OTCQB: CLABF ), (Frankfurt: LD6 , WKN: A3CSSU ) (the " Company ") is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc. (" Vocan ") has incorporated a state-of-the-art, high density, fermenting and bio-processing equipment platform (the " Platform ") into their proprietary biosynthetic psilocybin (the " Product ")... Read More

VANCOUVER, BC / ACCESSWIRE / July 7, 2023 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6), (WKN: A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly owned subsidiary, Vocan Biotechnologies Inc. ("Vocan"), has completed final steps of its research for its biosynthetic production system (the System) and has filed a patent under the Patent Cooperation Treaty (PCT) (the "Patent" or... Read More

VANCOUVER, BC / ACCESSWIRE / May 5, 2023 / Core One Labs Inc. (CSE: COOL )(OTCQB: CLABF )(Frankfurt: LD6) , (WKN:A3CSSU) (the " Company " or " Core One ") is pleased to announce that it is in discussions with several pharmaceutical laboratories and research organizations to supply them with active pharmaceutical ingredient (API) psilocybin to meet their psychedelic research needs. Scientific interest in psilocybin has grown... Read More

VANCOUVER, BC / ACCESSWIRE / May 1, 2023 / Core One Labs Inc. (CSE:COOL) (OTCQB:CLABF) (Frankfurt:LD6) (WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly-owned subsidiaries, GMP Drug Inc., and Awakened Biosciences Inc. ("Awakened") will commence the development and manufacturing of psychedelic prodrugs through its partnership with a compounding pharmacy (the " Pharmacy ") based in British... Read More

VANCOUVER, BC / ACCESSWIRE / April 21, 2023 / Core One Labs Inc. (CSE:COOL) (OTCQB:CLABF) (Frankfurt:LD6, WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly-owned subsidiary, Awakened Biosciences Inc. (the " Subsidiary " or " Awakened ") has successfully completed the first synthetic production of psilocin at the GMP manufacturing facility of its recently acquired GMP Drug Inc. (see Company... Read More

VANCOUVER, BC / ACCESSWIRE / January 24, 2023 / Core One Labs Inc. (CSE:COOL) (OTCQB:CLABF) (Frankfurt:LD6) (WKN: A3CSSU) (the "Company" or "Core One"), in follow-up to its press release dated September 16, 2022, is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (" Akome ") has finalized study parameters and signed a contract with Fundació Bosh I Gimpera, in representation of Universitat de Barcelona... Read More

VANCOUVER, BC / ACCESSWIRE / January 13, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt: LD6 )(WKN: A3CSSU) (the " Company " or " Core One "), is pleased to announce that it has acquired (the " Acquisition ") GMP Drug Inc. (" GMP Drug "), an arms-length privately held company that operates through a Good Manufacturing Practices (" GMP ") facility (the " Facility ") owned by a third-party located in Ontario,... Read More

VANCOUVER, BC / ACCESSWIRE / November 18, 2022 / Core One Labs Inc. (CSE: COOL ), (OTCQB: CLABF ), (Frankfurt: LD6 , WKN:A3CSSU) (the " Company " or " Core One ") is pleased to announce the initial production run of its psilocybin active pharmaceutical ingredient (API) product at a good manufacturing practices (GMP) facility is projected for January 2023, to test the Company's commercial production capabilities. After a... Read More

Core One Labs Inc. (CSE: COOL ), (OTCQB: CLABF ), (Frankfurt: LD6 , WKN:A3CSSU) (the " Company " or " Core One ") is pleased to announce, as a follow up to the Company's press release dated March 20, 2022, wherein the Company announced that it was actively working to investigate investment and potential takeover opportunities by strategic psychedelics or pharmaceutical companies, that the Company's Board of Directors is now... Read More

Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN:A3CSSU) (the " Company " or " Core One "), further to its press release dated August 18, 2022, is excited to announce its wholly owned subsidiary, Akome Biotech Ltd. (" Akome "), the Company's bio-pharma research and development division focused on new psychedelic-based drug discovery and development targeting neurological and mental health disorders, is... Read More

Core One Labs Inc. (CSE: COOL ) (OTCQB: CLABF ) (Frankfurt: LD6 ) (WKN:A3CSSU) (the " Company " or " Core One "), is pleased to announce that it is nearing good manufacturing practices (GMP) production of its psychedelic compounds, as the Company has progressed its negotiations with a certified facility and is developing a detailed plan to provide high quality and affordable psychedelic medicine to properly licensed clinics... Read More

Core One Labs Inc. (CSE: COOL )(OTCQB: CLABF )(Frankfurt: LD6) ( WKN: A3CSSU) (the " Company " or " Core One ") is pleased to announce that its wholly-owned subsidiary Awakened Biosciences Inc. (" Awakened ") has developed a groundbreaking proprietary method for isolating and purifying psilocybin from mushrooms biomass. This breakthrough will provide the company with the opportunity to partner and work with the growing... Read More

Core One Labs Inc. (CSE: COOL ), (OTCQB: CLABF ), (Frankfurt: LD6 , WKN:A3CSSU) (the " Company " or " Core One ") is pleased to announce it has entered into a Letter of Intent (the " LOI ") with Medelys Laboratories International Inc. (" Medelys ") dated effective September 21, 2022, for the purpose of manufacturing the Company's proprietary psychedelic active pharmaceutical ingredient (API) products for Core One and its... Read More

Core One Labs Inc. (CSE: COOL ), (OTCQB: CLABF ), (Frankfurt: LD6 , WKN:A3CSSU) (the " Company " or " Core One ") is pleased to announce that following the receipt of very positive results during phase one (" Phase 1 ") pre-clinical development studies conducted by its wholly owned subsidiary Akome Biotech Ltd. (" Akome "), and their research partners, relating to the neuroactivities of its selected bioactive-compounds (the... Read More

Second Ground Breaking Technological Advancement Core One Labs Inc. (CSE: COOL ), (OTCQB: CLABF ), (Frankfurt: LD6) ( WKN:A3CSSU) (the " Company " or " Core One ") is pleased to announce that scientists at its wholly-owned subsidiary Awakened Biosciences Inc. (" Awakened ") have successfully completed the breakthrough first step in producing API N, N-dimethyltryptamine ( DMT ), with the synthesis of a DMT precursor (the "... Read More

Core One Labs Inc. (CSE: COOL ), (OTCQB: CLABF ), (Frankfurt: LD6 )(WKN: A3CSSU) (the " Company " or " Core One ") announces that it has initiated rollout of its commercial sales strategy for its proprietary biosynthetic API psilocybin product. The Company's commercial sales strategy is a roadmap geared to securing dependable, long-term revenues for the Company through the acquisition and retention of new customers, while... Read More

Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN:A3CSSU) (the " Company " or " Core One "), a life sciences biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of novel delivery systems technology, is excited to announce that it... Read More

Core One Labs Inc. (CSE: COOL ), (OTCQB: CLABF ), (Frankfurt: LD6 , WKN:A3CSSU) (the " Company " or " Core One ") is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (" Akome ") through its formalized research agreement with Fundación Medina in Granada, Spain (" Fundación Medina ") has received very encouraging results from pharmacokinetics studies currently underway. The study results represent... Read More

Opening the Door to Expanded Patent Coverage Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN:A3CSSU) (the "Company" or "Core One"), further to its press release dated March 4, 2022, is excited to announce its wholly owned subsidiary, Akome Biotech Ltd. (" Akome "), the Company's bio-pharma research and development division focused on new psychedelic-based drug discovery and development targeting neurological... Read More

Core One Labs Inc. (CSE: COOL ), (OTCQB: CLABF ), (Frankfurt: LD6), (WKN:A3CSSU) (the " Company " or " Core One ") is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc. (" Vocan ") has successfully employed enzymatic production methods to convert a chemically produced psilocin developed by the Company's recently acquired Awakened Biosciences Inc.'s (" Awakened "), into viable API psilocybin.... Read More

Core One Labs Inc. (CSE: “ COOL ”), (OTCQB: “ CLABF ”), (Frankfurt: LD6, WKN: A3CSSU) (the “ Company ” or “ Core One ”) a life sciences biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of novel delivery systems technology is pleased to... Read More

Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “ Company ” or “ Core One ”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“ Akome ”) through a research arrangement with Neuro-Zone Srl, (“ Neuro-Zone ”) based in Bresso, Italy, has achieved positive results from its in vitro biological assay (“ bioassay ”) development studies (“ bioassay studies ”); furthering the... Read More

Core One Labs Inc. (CSE: COOL ), (OTC: CLABF ), (Frankfurt: LD6 , WKN: A3CSSU) (the “ Company ” or “ Core One ”) announces that following its recently announced developments it is actively working to investigate investment and potential takeover opportunities by strategic psychedelics or pharmaceutical companies. “Acquisition or investment by a major pharmaceutical company could be mutually beneficial. As more research comes... Read More

Core One Labs Inc. (CSE: COOL ), (OTC: CLABF ), (Frankfurt: LD6 , WKN: A3CSSU) (the “ Company ” or “ Core One ”) is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc. (“ Vocan ”) will collaborate with Core One’s recently acquired subsidiary, Awakened Biosciences Inc. (“ Awakened ”), in order to strengthen and enhance Vocan’s patented proprietary Psilocybin API production methods. The crucial... Read More

Core One Labs Inc. (CSE: COOL ), (OTC: CLABF ), (Frankfurt: LD6 , WKN: A3CSSU) (the “ Company ” or “ Core One ”) is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc. (“ Vocan ”) has set in motion steps to expand production of its proprietary biosynthesized psilocybin API (active pharmaceutical ingredient ), for utilization by pharmaceutical manufacturers involved in the development of... Read More

Core One Labs Inc. (CSE: COOL ), (OTC: CLABF ), (Frankfurt: LD6 , WKN: A3CSSU) (the “ Company ” or “ Core One ”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“ Akome ”), has entered into an agreement with the Universidad Complutense de Madrid (“Universidad Complutense”), officially commencing neurogenesis stimulation and modeling studies research, to advance the development of the Company’s... Read More

Core One Labs Inc. (CSE: COOL ), (OTC: CLABF ), (Frankfurt: LD6 , WKN: A3CSSU) (“ Core One ” or the “ Company ”), is pleased to announce that its wholly owned subsidiary, Vocan Biotechnologies Inc. (“ Vocan ”), has successfully tested its proof-of-concept for the production of biosynthetic N-methyltryptamine (NMT) (also known as monomethyl tryptamine (MMT)) for use in future upscaling capabilities. NMT, which belongs to the... Read More

A team of Vancouver scientists has discovered a new process to cost-effectively make psilocybin, the active ingredient in magic mushrooms, paving the way for greater and more affordable treatments for a range of addictions and mental health conditions. Recent research has found psilocybin is effective in the treatment of alcohol and opiate addiction, PTSD, depression, and anxiety. Research into other potential applications... Read More

Core One Labs Inc. (CSE: COOL ), (OTC: CLABF ), (Frankfurt: LD6 , WKN: A3CSSU) (“ Core One ” or the “ Company ”) is pleased to announce that its wholly-owned subsidiary, Vocan Biotechnologies Inc. of Victoria, British Columbia, has filed a patent application with the United States Patent and Trademark Office (“USPTO”) for the production of biosynthetic N-methyltryptamine ( NMT ) (also known as monomethyl tryptamine (MMT))... Read More

Core One Labs Inc. (CSE: COOL ), (OTC: CLABF ), (Frankfurt: LD6 , WKN: A3CSSU) (the “ Company ” or “ Core One ”), a life sciences biotechnology company focused on research, development, and production of API grade psychedelic compounds, as well as the advancement of psychedelic assisted treatments for various mental health and neurological disorders, is pleased to announce that it has completed the acquisition (the “... Read More

Core One Labs Inc. (CSE: COOL ), (OTC: CLABF ), (Frankfurt: LD6 , WKN: A3CSSU ) (“ Core One ” or the “ Company ”) is pleased to announce that, further to the Company’s press release dated April 21, 2021, the Company’s team of scientists at its wholly-owned subsidiary Vocan Biotechnologies Inc. (“ Vocan ”) has received positive results and believes that replication of its proprietary recombinant production system (the “... Read More

Core One Labs Inc. (CSE: COOL ), (OTC: CLABF ), (Frankfurt: LD6 , WKN: A3CSSU) (the “ Company ” or “ Core One ”) is pleased to announce that following its milestone announcement that its wholly-owned subsidiary, Vocan Biotechnologies Inc. ( Vocan ), has successfully engineered a novel recombinant production system for biologically synthesized (biosynthesized) psilocybin, and has filed for patent protection of its... Read More

Core One Labs Inc. (CSE: COOL ), (OTC: CLABF ), (Frankfurt: LD6 , WKN: A3CSSU) (the “ Company ” or “ Core One ”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has signed a consulting agreement with the Universitat de Barcelona (the “ University of Barcelona ” or the “ University ”), Faculty of Pharmacy and Food Sciences, Laboratory of Medicinal Chemistry, of Barcelona, Spain. By virtue... Read More

Core One Labs Inc. (CSE: COOL ), (OTC: CLABF ), (Frankfurt: LD6 , WKN: A3CSSU ) (“ Core One ” or the “ Company ”) is pleased to announce that its wholly owned subsidiary, Vocan Biotechnologies Inc. of Victoria, British Columbia, has optimized its recombinant production system (the “ System ”), successfully testing its proof of concept for the biosynthesis of psilocybin suitable for use in future scale-up and has filed a... Read More

Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“ Core One ” or the “ Company ”) announces that the special investor webcast (the “ Webcast ”) announced in the Company’s press release on Friday, January 14, 2022 and initially scheduled for Tuesday, January 18, 2022 at 1:30 p.m. PST/4:30 p.m. ET/10:30 p.m. CET, has been rescheduled to Friday, January 21, 2022 at 1:30 p.m. PST/4:30 p.m. ET/10:30... Read More

Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“ Core One ” or the “ Company ”) is pleased to announce, as a follow up to the press release dated January 10, that Dr. Robert E.W. Hancock, the Company’s Chairman, and CEO of its wholly owned subsidiary Vocan Biotechnologies Inc. will host a special investor webcast (the “ Webcast ”) on Tuesday, January 18, 2022 at 1:30 p.m. PST/4:30 p.m. ET/10:30... Read More

Core One Labs Inc. (CSE: COOL ), (OTC: CLABF ), (Frankfurt: LD6 , WKN: A3CSSU ) (“ Core One ” or the “ Company ”) is pleased to announce that it has progressed its work on biosynthesizing N,N-Dimethyltryptamine (“DMT”) and has been approved by Health Canada to add N,N-Dimethyltryptamine (“DMT”) to the schedule of approved controlled substances under the existing licence granted by the Controlled Drugs and Substances Act (”... Read More

Core One Labs Inc. (CSE: COOL ), (OTC: CLABF ), (Frankfurt: LD6 , WKN: A3CSSU) (the “ Company ” or “ Core One ”) applauds Health Canada for its recent amendment to the Special Access Programme ( SAP ), which will now allow physicians to request patient access to psychedelic treatments, including psilocybin-assisted therapy. The amendments under the SAP came into effect as of today, January 5, 2022, as published in the Canada... Read More

Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “ Company ” or “ Core One ”) is a research and development company focused on bringing psychedelic medicines to market through the development and production of API grade psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of novel delivery system technology. The Company is pleased to announce it has... Read More

Core One Labs Inc. (CSE: COOL ), (OTC: CLABD ), (FWB: LD6 , WKN: A3CSSU) (the “Company”) a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy, congratulates Seattle’s city council in their unanimous vote to decriminalize the use, possession and cultivation of naturally occurring entheogenic drugs,... Read More

Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“ Core One ” or the “ Company ”) is pleased to announce that Dr. Robert E.W. Hancock, the Company’s Chairman, and CEO of its wholly owned subsidiary Vocan Biotechnologies Inc. (“ Vocan ”) will be presenting at a Company hosted Virtual Town Hall meeting on Wednesday, August 4, 2021 at 1:30 p.m. PST/ 4:30 p.m. ET/ 22:30 p.m. CET. The Virtual Town Hall... Read More

Core One Labs Inc. (CSE: COOL ), (OTC: CLABD ), (Frankfurt: LD6 , WKN: A3CSSU) (the “ Company ” or “ Core One ”) is pleased to announce that it is pursuing a listing on the Capital Market tier of The Nasdaq Stock Market LLC (“ Nasdaq ”) to enhance the Company’s investor profile and increase value for its shareholders. The Company believes a Nasdaq listing (the “ Listing ”) will allow the Company to further US business... Read More

Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “ Company ”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“ Akome ”) has commenced the development of a next-generation psychedelic drug formulation for the purpose of mitigating neurological damage that results from ischemic strokes. Akome’s next generation psychedelic drug formulation for the mitigation of... Read More

Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “ Company ”) is pleased to announce it has retained Smart & Biggar LLP (“ Smart and Biggar ”) to handle all IP filings for Akome Biotech Ltd. (“ Akome ”) and Vocan Biotechnologies Inc. (“ Vocan ”). Smart & Biggar is Canada’s largest and highest-ranked intellectual property law firm. Smart and Biggar’s award-wining IP team has helped the most... Read More

Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) advises that in preparation of a potential listing of its common shares on the Capital Market tier of The Nasdaq Stock Market LLC (“Nasdaq” or the “Exchange”), the Company is planning a share consolidation of its outstanding common share capital on the basis of eight (8) pre-Consolidation shares for every one (1)... Read More

Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “ Company ”) is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc. (“ Vocan ”), a company operating under one of few Health Canada Controlled Drugs and Substances Dealer’s labs, is pleased to announce that it is in the final stages of completing its provisional patent application for the protection of its... Read More

Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62, WKN:A2P8K3) (the " Company " or " Core One "). This news release is issued at the request of the Investment Industry Regulatory Organization of Canada (" IIROC ") and the Canadian Securities Exchange (" CSE "). Statements made in the news release issued by the Company on May 4, 2021 indicated that the Company had been made aware of potentially manipulative trading... Read More

VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “ Company ” or “ Core One ”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“ Akome ”) has commenced the development of its next-generation patent pending psychedelic drug formulation for the treatment of Alzheimer’s Disease (“ Alzheimer’s ”). Akome’s... Read More

Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “ Company ” or “ Core One ”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“ Akome ”) has commenced the development of its next-generation patent pending psychedelic drug formulation for the treatment of Alzheimer’s Disease (“ Alzheimer’s ”). Akome’s ‘next-generation’ psychedelic drug formulation, also known as... Read More

Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “ Company ” or “ Core One ”) is pleased to announce it has appointed Dr. Santiago Ferro, Chief Executive Officer of Akome Biotech Ltd. (“ Akome ”), as Chief Medical Officer of the Company. Dr. Ferro will lead the Company through clinical trials and commercialization of its psychedelic products. Dr. Ferro is a graduate of Javeriana University... Read More

Core One Labs Inc. (CSE:COOL) (OTC PINK:CLABF) (Frankfurt:LD62) (WKN: A2P8K3) (the " Company " or " Core One ") wishes to confirm that management is unaware of any material change in the Company's operations that would account for the recent and significant share price depreciation in the Company's stock. The Company has been informed by its advisers that sophisticated techniques including spoofing, layering, wash trading,... Read More

Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce that it has completed the acquisition (the “Transaction”) of Akome Biotech Ltd. (“Akome”). With this strategic acquisition, the scope of Core One’s psychedelics’ bio-pharma... Read More

Core One Labs Inc. (CSE:COOL) (OTC PINK:CLABF) (FRA:LD62) (WKN:A2P8K3) (the "Company") is pleased to announce it has appointed Dr. Dan Polonenko to its Advisory Board, effective immediately. Dr. Polonenko has also agreed to consult the Company and will assist in the filing of any patents the Company intends to file. Dr. Polonenko is a Principal and Registered Patent Agent in Gowling WLG's Calgary office. His practice... Read More

Core One Labs Inc. (CSE:COOL) (OTC PINK:CLABF) (FRA:LD62) (WKN:A2P8K3) (the "Company") a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce it has signed letter of intent (the "LOI") to acquire all of the outstanding share capital (the "Proposed Transaction") of Akome Biotech Ltd. ("Akome").. Akome is a developer of psychedelic-based... Read More

Core One Labs Inc. (CSE:COOL) (OTC PINK:CLABF) (FRA:LD62) (WKN:A2P8K3) (the " Company " or " Core One ") announces that it has reached an agreement with Plant-Based Investment Corp. (formerly, Cannabis Growth Opportunity Corporation) (PBIC) (" PBIC ") to rescind the share exchange transaction previously completed between the parties (the " Share Exchange "). Effective March 16, 2020, the Company subscribed for and acquired... Read More

Core One Labs Inc. (CSE:COOL) (OTC PINK:CLABF) (Frankfurt:LD62) (WKN: A2P8K3) (the " Company " or " Core One ") is pleased to announce its wholly-owned subsidiary Vocan Biotechnologies Inc. (" Vocan ") has expanded its product commercialization team, adding Dr. Elizabeth Matthews as Head of Scientific and Regulatory Affairs. Dr. Matthews will oversee research and development, as well as the commercialization of Vocan's new... Read More

Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) WKN: A2P8K3) (" Core One " or the " Company "), a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy, is pleased to announce it has completed the acquisition (the " Transaction ") of Ketamine Infusions Centers of Texas Inc. (" KICT" ), a... Read More

Core One Labs Inc. (CSE:COOL) (OTC PINK:CLABF) (FRA:LD62) (WKN:A2P8K3) (the " Company ") is pleased to announce that its wholly owned subsidiary Rejuva Mental Health Clinic (the "Clinic") has retained Dr. Stephen Peach as Lead Physician. Dr. Peach will be responsible for developing comprehensive patient intake and assessment protocols, with the goal of identifying individuals with a history of mental health disorders and... Read More

VANCOUVER, BC / ACCESSWIRE / March 14, 2021 / Core One Labs Inc. (CSE:COOL) (OTC PINK:CLABF) (FRA:LD62) (WKN: A2P8K3) (the " Company ") a research and technology company focused on life sciences and bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy, is pleased to announce that the Financial Industry Regulatory Authority has accepted the Company's Form 211 for... Read More

The Developer of Psychedelic Treatments Enters the Telehealth Space with Access to Close to 80,000 Clinic Patients Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the " Company " or " Core One ") announces that it has completed the acquisition (the " Transaction ") of all of the outstanding share capital of Bluejay Mental Health Group Inc. (" Bluejay " or " Bluejay Mental Health ") effective... Read More

Core One Labs Inc. (CSE:COOL) (OTC PINK:CLABF) (FSE:LD62) (WKN:A2P8K3) (the " Company ") is pleased to announce that in collaboration with Ketamine Infusions Centers of Texas LLC (KICT) it is exploring a development program for N-dimethyltryptamine (DMT) assisted psychotherapy to address anxiety and depression. In December 2020, the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom (UK)... Read More

Core One Labs Inc. (CSE:COOL), (OTC:CLABF), (Frankfurt:LD62, WKN: A2P8K3) (the " Company ") is pleased to announce that its wholly owned subsidiary Vocan Biotechnologies Inc. has entered into a term sheet with Vocan Brazil Biotechnologies Inc. (" Vocan Brazil ") for the licensing of its proprietary technology. Vocan Brazil is owned by Brazilian entrepreneur Mr. Marcelo Galvão, an arm's length party. The Company has licensed... Read More

Core One Labs Inc. (CSE:COOL), (OTC PINK:CLABF), (Frankfurt:LD62, WKN: A2P8K3) (the "Company" or "Core One") a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce readiness to begin initial biosynthetic psilocybin production trials. The Company's wholly owned subsidiary, Vocan Biotechnologies Inc. of Victoria, British Columbia, has... Read More

Core One Labs Inc. (CSE:COOL) (OTC PINK:CLABF) (Frankfurt:LD62) (WKN:A2P8K3) (the " Company " or " Core One ") a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy is pleased to announce it has entered into a definitive agreement to acquire (the " Transaction ") Ketamine Infusion Centers of Texas Inc. (... Read More

Core One Labs Inc. (CSE:COOL) (OTC PINK:CLABF) (Frankfurt:LD62) (WKN: A2P8K3) (" Core One " the " Company ") is pleased with the tremendous turnout on the International Investors' Call held earlier today. Core One's Chairman, Dr. Robert E.W. Hancock and Chief Executive Officer, Joel Shacker provided participants an update on... Read More

Core One Labs Inc. (CSE:COOL) (OTC Pink:CLABF) (Frankfurt:LD62, WKN:A2P8K3) (the " Company " or " Core One Labs ") a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce preparations for filing a patent application encompassing its... Read More

Core One Labs Inc. (CSE:COOL) (OTC PINK:CLABF) (Frankfurt::LD62) (WKN: A2P8K3) (the " Company ") is pleased to announce that it has added video conference capabilities to its previously announced teleconference call scheduled for Wednesday, February 10, 2021 at 1:30 p.m. PST, 4:30 p.m. EST and 10:30 p.m. CET, with Dr. Robert... Read More

Core One Labs Inc. (CSE:COOL) (OTC PINK:CLABF) (Frankfurt:LD62) (WKN:A2P8K3) (the "Company") announces that it has engaged Donohoe Advisory Associates LLC ("Donohoe Advisory") in connection with its efforts to seek a listing for its common shares on a NASDAQ Stock Market. The Company expects that listing its common shares on... Read More

Core One Labs Inc. (CSE:COOL) (OTC PINK:CLABF) (Frankfurt:LD62) (WKN: A2P8K3) (the " Company ") a biotechnology research and development company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy is pleased to announce it has entered... Read More

Core One Labs Inc. (CSE:COOL) (OTC PINK:CLABF) (Frankfurt:LD62) (WKN:A2P8K3) (the " Company ") is pleased to announce its wholly-owned subsidiary Vocan Biotechnologies Inc. (" Vocan ") has assembled the necessary equipment, which will allow the laboratory to commence the process of recombinant production of psilocybin. The... Read More